New Criteria Developed for Appropriate Use of Amyloid, Tau PET

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 17, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 17, 2025 -- Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer's Association and the Society for Nuclear Medicine and Molecular Imaging and published online Jan. 8 in both Alzheimer's & Dementia and the Journal of Nuclear Medicine.

Gil D. Rabinovici, M.D., from the University of California San Francisco, and colleagues updated AUC for amyloid PET and developed AUC for tau PET. Key research questions that guided a systematic literature review on clinical amyloid/tau PET were identified. Based on this review, 17 clinical scenarios were developed in which amyloid or tau PET may be considered.

The researchers found that seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate for amyloid PET. Five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate for tau PET. Both amyloid and tau PET are considered appropriate for patients presenting with mild cognitive impairment (MCI) or dementia who are younger than 65 years and in whom Alzheimer disease (AD) pathology is suspected; for patients presenting with MCI or dementia syndrome that could be consistent with AD pathology but has atypical features; to inform the prognosis of patients presenting with MCI due to clinically suspected AD pathology; and to determine eligibility for treatment with an approved amyloid-targeting therapy.

"Amyloid and tau PET can support and enable earlier and more accurate diagnosis, which is essential to high quality care and treatment for dementia, providing appropriate support services and future planning," Rabinovici said in a statement.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Abstract/Full Text: Alzheimer's & Dementia

Abstract/Full Text: Journal of Nuclear Medicine

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-18 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords